Skip to Content


You are viewing the 1st of the 2 courses UPMC Physician Resources permits you to view without registering. To have full access to our FREE courses on our website, please register or log in now.

Dr. Mark Gladwin focuses his presentation on the clinical presentation, initial screening, clinical workup, and risk stratification of pulmonary hypertension.

Educational objectives:

Upon completion of this activity, participants should be able to:

  • Identify and diagnose PAH in the clinic
  • Discuss PAH treatment
  • Review adjustments to PAH treatments based on patient response

Reading Resources:

  1. Forfia et al. Am J Respir Crit Care Med 2006; 174:1034-41
  2. Thabut G Chest 2005;127:1531-6.
  3. Lam SP JACC 2009; 53: 1119–26.
  4. Lai, Gladwin. Circulation Research 2014.
  5. McLaughlin and McGoon. Circulation 2006;114:1417-31.


Dr. Gladwin has financial interests with the following entity or entities producing health care goods or services as indicated below:

  • Grant/Research Support:Dr. Gladwin receives research support from Globin Solutions, Inc. Dr. Gladwin is a principal-investigator in a research collaboration with Bayer Pharmaceuticals to evaluate riociguate as a treatment for patients with SCD.
  • Consultant: Dr. Gladwin has served as a consultant for Epizyme, Inc., Actelion Clinical Research, Inc., Acceleron Pharma, Inc., Catalyst Biosciences, Inc., Modus
  • Other: Dr. Gladwin is a co-inventor of patents and patent applications directed to the use of recombinant neuroglobin and heme-based molecules as antidotes for CO poisoning

All presenters disclosure of relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients is listed above.  No other planners, members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose.

Accreditation Statement:

The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Pittsburgh School of Medicine designates this enduring material for a maximum of .75 AMA PRA Category 1 Credits™. Each physician should only claim credit commensurate with the extent of their participation in the activity. Other health care professionals are awarded (0.075) continuing education units (CEU) which are equivalent to .75 contact hour.

For your credit transcript, please access our website 4 weeks post-completion at and follow the link to the Credit Transcript page. If you do not provide the last 5 digits of your SSN on the next page you will not be able to access a CME credit transcript. Providing your SSN is voluntary.

ABIM MOC Part 2 Credit

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.  

To receive your ABIM MOC Part 2 credit, you will need to complete the post-test with a pass rate of 100% and provide your date of birth and ABIM number, along with the other required fields.  This information will be shared with the American Board of Internal Medicine using the Accreditation Council for Continuing Medical Education Program and Activity Reporting System.

Release Date: 3/10/2017 | Last Modified On: 3/31/2020 | Expires: 2/10/2021

This course has been expired.